US20210346322A1 - Compounds for use in the treatment of cancer - Google Patents
Compounds for use in the treatment of cancer Download PDFInfo
- Publication number
- US20210346322A1 US20210346322A1 US17/380,195 US202117380195A US2021346322A1 US 20210346322 A1 US20210346322 A1 US 20210346322A1 US 202117380195 A US202117380195 A US 202117380195A US 2021346322 A1 US2021346322 A1 US 2021346322A1
- Authority
- US
- United States
- Prior art keywords
- artd10
- formula
- group
- alkyl
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 62
- 206010028980 Neoplasm Diseases 0.000 title abstract description 28
- 201000011510 cancer Diseases 0.000 title abstract description 19
- 238000011282 treatment Methods 0.000 title description 17
- XZRCQWLPMXFGHE-UHFFFAOYSA-N 4-(4-carbamoylphenoxy)benzamide Chemical compound C1=CC(C(=O)N)=CC=C1OC1=CC=C(C(N)=O)C=C1 XZRCQWLPMXFGHE-UHFFFAOYSA-N 0.000 claims abstract description 45
- 229910052760 oxygen Inorganic materials 0.000 claims description 22
- 125000004429 atom Chemical group 0.000 claims description 21
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 14
- 125000000623 heterocyclic group Chemical group 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 125000006274 (C1-C3)alkoxy group Chemical class 0.000 claims description 13
- 229920006395 saturated elastomer Polymers 0.000 claims description 13
- 229910052799 carbon Inorganic materials 0.000 claims description 11
- 229910052757 nitrogen Inorganic materials 0.000 claims description 11
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 10
- 229910052731 fluorine Inorganic materials 0.000 claims description 9
- 239000001301 oxygen Substances 0.000 claims description 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 8
- 229910052794 bromium Inorganic materials 0.000 claims description 8
- 229910052801 chlorine Inorganic materials 0.000 claims description 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 8
- 229910052740 iodine Inorganic materials 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- -1 —OH Chemical class 0.000 claims description 8
- 125000003178 carboxy group Chemical class [H]OC(*)=O 0.000 claims description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- 125000001424 substituent group Chemical group 0.000 claims description 7
- 229910052717 sulfur Inorganic materials 0.000 claims description 7
- 125000004432 carbon atom Chemical group C* 0.000 claims description 5
- 239000000872 buffer Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 239000003381 stabilizer Substances 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 230000002335 preservative effect Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 abstract description 35
- 102000009062 ADP Ribose Transferases Human genes 0.000 abstract description 18
- 108010049290 ADP Ribose Transferases Proteins 0.000 abstract description 18
- 101000613614 Homo sapiens Protein mono-ADP-ribosyltransferase PARP10 Proteins 0.000 abstract description 11
- 102000004190 Enzymes Human genes 0.000 abstract description 10
- 108090000790 Enzymes Proteins 0.000 abstract description 10
- 239000003814 drug Substances 0.000 abstract description 9
- 238000000338 in vitro Methods 0.000 abstract description 9
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 abstract description 6
- 102100040847 Protein mono-ADP-ribosyltransferase PARP10 Human genes 0.000 abstract description 5
- 206010013023 diphtheria Diseases 0.000 abstract description 4
- 101710127122 Protein mono-ADP-ribosyltransferase PARP10 Proteins 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 30
- 230000000694 effects Effects 0.000 description 19
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 17
- 230000027455 binding Effects 0.000 description 16
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 14
- 238000000034 method Methods 0.000 description 14
- 0 **C1=CC=C2C(=O)NCCC2=C1 Chemical compound **C1=CC=C2C(=O)NCCC2=C1 0.000 description 10
- 238000003556 assay Methods 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- GSCPDZHWVNUUFI-UHFFFAOYSA-N 3-aminobenzamide Chemical compound NC(=O)C1=CC=CC(N)=C1 GSCPDZHWVNUUFI-UHFFFAOYSA-N 0.000 description 9
- 101000613542 Homo sapiens Protein mono-ADP-ribosyltransferase PARP16 Proteins 0.000 description 9
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 9
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 description 9
- 102100040905 Protein mono-ADP-ribosyltransferase PARP16 Human genes 0.000 description 9
- 230000003197 catalytic effect Effects 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 229960001330 hydroxycarbamide Drugs 0.000 description 9
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 8
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 8
- 102100040848 Protein mono-ADP-ribosyltransferase PARP14 Human genes 0.000 description 8
- 101710144588 Poly [ADP-ribose] polymerase 1 Proteins 0.000 description 7
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 7
- 101710127121 Protein mono-ADP-ribosyltransferase PARP14 Proteins 0.000 description 7
- 229960003966 nicotinamide Drugs 0.000 description 7
- 235000005152 nicotinamide Nutrition 0.000 description 7
- 239000011570 nicotinamide Substances 0.000 description 7
- 102100023652 Poly [ADP-ribose] polymerase 2 Human genes 0.000 description 6
- 102100040845 Protein mono-ADP-ribosyltransferase PARP12 Human genes 0.000 description 6
- 102100034931 Protein mono-ADP-ribosyltransferase PARP4 Human genes 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 6
- 239000013078 crystal Substances 0.000 description 6
- 238000002022 differential scanning fluorescence spectroscopy Methods 0.000 description 6
- 125000004404 heteroalkyl group Chemical group 0.000 description 6
- 208000027866 inflammatory disease Diseases 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
- 238000003032 molecular docking Methods 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 230000005730 ADP ribosylation Effects 0.000 description 5
- 101000613620 Homo sapiens Protein mono-ADP-ribosyltransferase PARP15 Proteins 0.000 description 5
- 101710144590 Poly [ADP-ribose] polymerase 2 Proteins 0.000 description 5
- 101710127119 Protein mono-ADP-ribosyltransferase PARP12 Proteins 0.000 description 5
- 102100040846 Protein mono-ADP-ribosyltransferase PARP15 Human genes 0.000 description 5
- 102100034935 Protein mono-ADP-ribosyltransferase PARP3 Human genes 0.000 description 5
- 101710204725 Protein mono-ADP-ribosyltransferase PARP4 Proteins 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 239000000460 chlorine Substances 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- FDLYAMZZIXQODN-UHFFFAOYSA-N olaparib Chemical compound FC1=CC=C(CC=2C3=CC=CC=C3C(=O)NN=2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FDLYAMZZIXQODN-UHFFFAOYSA-N 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 230000005778 DNA damage Effects 0.000 description 4
- 231100000277 DNA damage Toxicity 0.000 description 4
- 230000033616 DNA repair Effects 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 229910014130 Na—P Inorganic materials 0.000 description 4
- 239000012661 PARP inhibitor Substances 0.000 description 4
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 description 4
- 102100037664 Poly [ADP-ribose] polymerase tankyrase-1 Human genes 0.000 description 4
- 101710129670 Poly [ADP-ribose] polymerase tankyrase-1 Proteins 0.000 description 4
- 102100037477 Poly [ADP-ribose] polymerase tankyrase-2 Human genes 0.000 description 4
- 101710129674 Poly [ADP-ribose] polymerase tankyrase-2 Proteins 0.000 description 4
- 101710204718 Protein mono-ADP-ribosyltransferase PARP3 Proteins 0.000 description 4
- 102100028882 Zinc finger CCCH-type antiviral protein 1 Human genes 0.000 description 4
- 101710087130 Zinc finger CCCH-type antiviral protein 1 Proteins 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 229960003722 doxycycline Drugs 0.000 description 4
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 3
- 208000032612 Glial tumor Diseases 0.000 description 3
- 206010018338 Glioma Diseases 0.000 description 3
- 206010033128 Ovarian cancer Diseases 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- 108010064218 Poly (ADP-Ribose) Polymerase-1 Proteins 0.000 description 3
- 229940124639 Selective inhibitor Drugs 0.000 description 3
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 230000005754 cellular signaling Effects 0.000 description 3
- 230000005757 colony formation Effects 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229960000572 olaparib Drugs 0.000 description 3
- 230000002018 overexpression Effects 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 239000007989 BIS-Tris Propane buffer Substances 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 230000005971 DNA damage repair Effects 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 101000826077 Homo sapiens SRSF protein kinase 2 Proteins 0.000 description 2
- ARHAVVDXPGTLBI-UHFFFAOYSA-N NC(=O)C1=CC=C(OCC2=C(F)C=CC=C2)C=C1 Chemical compound NC(=O)C1=CC=C(OCC2=C(F)C=CC=C2)C=C1 ARHAVVDXPGTLBI-UHFFFAOYSA-N 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 230000018199 S phase Effects 0.000 description 2
- 102100023015 SRSF protein kinase 2 Human genes 0.000 description 2
- 150000001408 amides Chemical group 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 150000001565 benzotriazoles Chemical class 0.000 description 2
- HHKZCCWKTZRCCL-UHFFFAOYSA-N bis-tris propane Chemical compound OCC(CO)(CO)NCCCNC(CO)(CO)CO HHKZCCWKTZRCCL-UHFFFAOYSA-N 0.000 description 2
- 201000008275 breast carcinoma Diseases 0.000 description 2
- 208000002458 carcinoid tumor Diseases 0.000 description 2
- 108020001778 catalytic domains Proteins 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000010293 colony formation assay Methods 0.000 description 2
- 239000003596 drug target Substances 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 231100000024 genotoxic Toxicity 0.000 description 2
- 230000001738 genotoxic effect Effects 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 201000005787 hematologic cancer Diseases 0.000 description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 2
- 150000002473 indoazoles Chemical class 0.000 description 2
- ATHLLZUXVPNPAW-UHFFFAOYSA-N lamellarin d Chemical compound C1=C(O)C(OC)=CC(C2=C3C4=CC(OC)=C(O)C=C4C=CN3C3=C2C=2C=C(OC)C(O)=CC=2OC3=O)=C1 ATHLLZUXVPNPAW-UHFFFAOYSA-N 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 229940100352 lynparza Drugs 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 230000005731 poly ADP ribosylation Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000003590 rho kinase inhibitor Substances 0.000 description 2
- 108010041788 rho-Associated Kinases Proteins 0.000 description 2
- 102000000568 rho-Associated Kinases Human genes 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000001542 size-exclusion chromatography Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- UTBMZXVFYWDCLT-UHFFFAOYSA-N 4-piperidin-4-yloxybenzamide;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=CC(C(=O)N)=CC=C1OC1CCNCC1 UTBMZXVFYWDCLT-UHFFFAOYSA-N 0.000 description 1
- DRGDTLQIXCUSGF-UHFFFAOYSA-N 5-chloro-2-methoxy-4-piperidin-4-yloxybenzamide Chemical compound C1=C(C(N)=O)C(OC)=CC(OC2CCNCC2)=C1Cl DRGDTLQIXCUSGF-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000011594 Autoinflammatory disease Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 101001113487 Gallus gallus Poly [ADP-ribose] polymerase 1 Proteins 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101001113440 Homo sapiens Poly [ADP-ribose] polymerase 2 Proteins 0.000 description 1
- 101000613617 Homo sapiens Protein mono-ADP-ribosyltransferase PARP12 Proteins 0.000 description 1
- 101000613615 Homo sapiens Protein mono-ADP-ribosyltransferase PARP14 Proteins 0.000 description 1
- 101000735456 Homo sapiens Protein mono-ADP-ribosyltransferase PARP3 Proteins 0.000 description 1
- 101000735463 Homo sapiens Protein mono-ADP-ribosyltransferase PARP4 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 208000005615 Interstitial Cystitis Diseases 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 208000001738 Nervous System Trauma Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 229910021586 Nickel(II) chloride Inorganic materials 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 102000000505 Ribonucleotide Reductases Human genes 0.000 description 1
- 108010041388 Ribonucleotide Reductases Proteins 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 208000033781 Thyroid carcinoma Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 201000006083 Xeroderma Pigmentosum Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 150000003936 benzamides Chemical class 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000013507 chronic prostatitis Diseases 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- 238000013104 docking experiment Methods 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 201000007487 gallbladder carcinoma Diseases 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 208000010749 gastric carcinoma Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- VDBNYAPERZTOOF-UHFFFAOYSA-N isoquinolin-1(2H)-one Chemical class C1=CC=C2C(=O)NC=CC2=C1 VDBNYAPERZTOOF-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000010859 live-cell imaging Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 208000028412 nervous system injury Diseases 0.000 description 1
- 208000007538 neurilemmoma Diseases 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- QMMRZOWCJAIUJA-UHFFFAOYSA-L nickel dichloride Chemical compound Cl[Ni]Cl QMMRZOWCJAIUJA-UHFFFAOYSA-L 0.000 description 1
- 231100000065 noncytotoxic Toxicity 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 108091008819 oncoproteins Proteins 0.000 description 1
- 102000027450 oncoproteins Human genes 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 229950005566 picoplatin Drugs 0.000 description 1
- IIMIOEBMYPRQGU-UHFFFAOYSA-L picoplatin Chemical compound N.[Cl-].[Cl-].[Pt+2].CC1=CC=CC=N1 IIMIOEBMYPRQGU-UHFFFAOYSA-L 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 208000001608 teratocarcinoma Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 208000013077 thyroid gland carcinoma Diseases 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000004906 unfolded protein response Effects 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/46—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/91091—Glycosyltransferases (2.4)
- G01N2333/91142—Pentosyltransferases (2.4.2)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Abstract
Description
- The present invention relates to the field of enzyme inhibitors useful for cancer treatments. Particularly, the present invention provides inhibitors of human diphtheria toxin-like ADP-ribosyltransferase 10 (ARTD10/PARP10). ARTD enzymes are ADP-ribosyltransferases having various activities in cellular signaling, DNA repair, apoptosis and cell proliferation. In particular, ARTD10 is a mono-ADP-ribosyltransferase. The benzamide comprising compounds disclosed in the present invention are small molecule inhibitors suitable for use as a medicine and in the treatment of cancers such as hematopoietic cancers, osteosarcoma, breast carcinoma, liver cancer, pancreatic cancer, pancreatic glioma and pancreatic carcinoid.
- The human diphtheria toxin-like ADP-ribosyltransferase (ARTD or PARP) family includes 17 members that share a conserved catalytic domain responsible for ADP-ribosylation of substrate proteins1-3. While some ARTDs modify substrates by transferring iteratively multiple ADP-ribose units resulting in poly-ADP-ribosylation (PARylation), most ARTDs mono-ADP-ribosylate (MARylate) their substrates4.
- PARylating ARTDs (pARTDs; ARTD1-6), most prominently ARTD1/PARP1, have been the focus of cancer related research during the past two decades. The ARTD1 inhibitor olaparib (Lynparza) has been approved to treat ovarian cancer with BRCA mutations30. However, olaparib as well as several other ARTD1 inhibitors are not specific11, which indicates that further studies are required to evaluate the contribution of different ARTDs to the phenotypes observed. This is relevant because recent studies have linked MARylating ARTDs (mARTDs) to cancer biology12. Notably, ARTD10/PARP10 has been suggested to be a potential drug target in cancer5.
- MARylation, a covalent reversible post-translational modification of proteins, is associated with various cellular processes13,14. ARTD10 was first identified as a binding partner of the oncoprotein c-Myc and it was the first member of the ARTD family to be fully characterized as an mARTD4. ARTD10 has a conserved C-terminal ART domain responsible for its enzymatic activity2-4,15. In vitro screening of more than 8000 proteins identified 78 substrates for ARTD1010, the majority of these being kinases. ADP-ribosylation of GSK3-β by ARTD10 negatively regulates the kinase activity of GSK3-β in vitro and knockdown of ARTD10 increased the kinase activity of GSK3-β in cells10.
- Other prior art relating to PARP inhibitors are:
-
- WO2015051766 disclosing amide substituted indazoles and benzotriazoles which are inhibitors of the enzyme poly (ADP-ribose) polymerase (PARP). Said amide substituted indazoles and benzotriazoles were disclosed to be useful as mono-therapies in tumors with specific defects in DNA-repair pathways;
- WO2014201972 disclosing benzimidazole-2-piperazine heterocyclic derivative and pharmaceutical composition comprising the same, and use of the derivative as a therapeutic agent, particularly as a poly (ADP-ribose) polymerase (PARP) inhibitor; and
- U.S. Pat. No. 8,993,594 disclosing substituted isoquinolin-1(2H)-one derivatives which selectively inhibit the activity of poly (ADP-ribose) polymerase PARP-1 with respect to poly (ADP-ribose) polymerase PARP-2. The compounds were disclosed to be useful in treating diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation.
- Further, U.S. Pat. No. 8,980,902 and US2015/031,652 disclose compounds that may be used to inhibit PARP.
- EP1500643 discloses benzamide derivatives inhibiting Rho kinase. The authors disclose that morbidity due to diseases such as hypertension and cancers is expected to be improved by inhibition of the Rho kinase and the Na+/H+ exchange transport system. It is also disclosed that cancers are improved by the effect of Rho kinase inhibitors on cell overproliferation. Examples of EP1500643 specifically disclose 4-(piperidin-4-yloxy)benzamide trifluoroacetate and 5-chloro-2-methoxy-4-(piperidin-4-yloxy)benzamide as potential Rho kinase inhibitors.
- Growing interest in the development of ARTD inhibitors culminated in the recent approval of the ARTD1-4 inhibitor Olaparib (Lynparza) for the treatment of ovarian cancer30. The less studied members of the superfamily, mARTDs, have recently attracted attention as potential new drug targets11,22-24. It is clear that the existing ARTD inhibitors are not selective and, although they inhibit certain mARTDs, they cannot be used to evaluate the cellular effects of inhibiting these enzymes11. Intracellular MARylation plays multiple roles in cancer biology as it is involved in cellular signaling events including stress and immune responses5,9,14,25. Hence there is a need to identify new more specific inhibitors to be used as research tools and to evaluate mARTDs as potential drug targets.
- It is an aim of the present invention to provide inhibitors of human ARTD10 for use as a medicine.
- It is another aim of the invention to provide compounds for use as human mono ADP-ribosyltransferase (mARTD) inhibitors in vitro.
- In the present invention, it has been discovered that human ARTD10, which belongs to an enzyme family linked to cancer biology, can be specifically inhibited by the compounds disclosed in the invention.
- Thus, in one aspect the invention provides a compound having a general formula
- wherein:
- the CLOSURE structure provides part of a 5-7-membered unsaturated or saturated heterocyclic group or alternatively the CLOSURE structure is absent, wherein the CLOSURE structure is replaced by hydrogen atoms H and/or H2;
- L represents a linker of 1, 2, 3 or 4 linking atom(s) in a linear or in a branched conformation, and being selected from the group consisting of: C, O, N or S, wherein at least one of the linking atoms is oxygen (O);
- R is a saturated or unsaturated C1-6 alkyl, saturated or unsaturated cycloalkyl, saturated or unsaturated heteroalkyl or a saturated or unsaturated heterocyclic ring system consisting of 1 or 2 heterocyclic rings, wherein said alkyl, cycloalkyl, heteroalkyl or ring system may contain at least one substituent selected from a group consisting of: H, F, Cl, Br, I, C1-3 alkyl, halogen-substituted C1-3 alkyl, C1-3 alkoxy, halogen-substituted C1-3 alkoxy, —CN, —OH, —COOH, —CONH2 and —NO2,
- and wherein L is O, R is not piperidin-4-yl or piperidin-4-yl with a Cl-substituent;
- or a tautomer, stereoisomer or a pharmaceutically acceptable salt thereof; for use as a medicine.
- In another aspect, the invention provides a pharmaceutical composition comprising a human ARTD10 inhibitor as defined in the invention and a pharmaceutically acceptable carrier, excipient, or stabilizer.
- In another aspect, the invention provides a use of a human ARTD10 inhibitor as defined in the invention for the manufacture of a medicament.
- In another aspect, the invention provides a method of treating cancer comprising a step of administering a human ARTD10 inhibitor as defined in the invention to a patient suffering from a cancer.
- In another aspect, the invention provides a method of treating inflammatory disorder comprising a step of administering a human ARTD10 inhibitor as defined in the invention to a patient suffering from an inflammatory disorder.
- In another aspect, the invention provides a use of a human ARTD10 inhibitor as defined in the invention as a mono ADP-ribosyltransferase (mARTD) inhibitor in vitro.
-
FIG. 1 . Chemical structures of OUL35; inactive analogs OUL77 and OUL78; general ARTD inhibitor 3AB; and a dose-response curve for OUL35 against ARTD10. -
FIG. 2 . Comparison of the docking pose with the crystal structure of ARTD10 (a) 3-aminobenzamide (3AB) in complex with ARTD10 (PDB id. 3HKV) (b) Docking pose of OUL35 with ARTD10. OUL35 is expected to bind to the nicotinamide site in a similar manner to 3AB. -
FIG. 3 . OUL35 rescues ARTD10 overexpressing cells (a) Images of the wells from colony formation experiments. ARTD10 expression was not induced in cells in the control wells, while the expressions of ARTD10 and the inactive mutant ARTD10-GW (G888W) were induced with doxycycline (Dox, 500 ng/ml) in the rest of the wells. The different compounds were added as indicated with a final concentration of 10 μM. These were replenished every 48 h. (b) Quantification of the colony formation results. The data represent mean values of three independent experiments performed in duplicates with standard deviations. -
FIG. 4 . The effect of OUL35 on HeLa cells treated with hydroxyurea. Cell confluence is indicated at 72 hours (n=5, data present mean±SEM , n.s=not significant, *P<0.05, **P<0.01). -
FIG. 5 . Dose-response curves for example compounds against ARTD10. On X-axis concentration (LOG, M) and on Y-axis Fluorescence. -
FIG. 6 . Examples of structures with an O-linker having inhibiting effect against ARTD10. -
FIG. 7 . Examples of structures with a longer O-linker having inhibiting effect against ARTD10. - ADP-ribosylation of proteins by human diphtheria toxin-like ADP-ribosyltransferase 10 (ARTD10) plays important roles in various activities ranging from cellular signaling, DNA repair and cell proliferation to the immune response. Here we describe small molecule ARTD10 inhibitors, the first reported selective and potent inhibitors for this enzyme and so far the only selective inhibitors of any of the mono-ADP-ribosyltransferases in the ARTD family. We show in the Experimental Section below that these compounds can be selective among the homologous ARTD enzyme family, rescue HeLa cells from ARTD10 induced cell death and also sensitize the cells to hydroxyurea induced DNA damage.
- The present invention is thus directed to a compound having a general formula
- wherein:
- the CLOSURE structure provides part of a 5-7-membered unsaturated or saturated heterocyclic group or alternatively the CLOSURE structure is absent, wherein the CLOSURE structure is replaced by hydrogen atoms H and/or H2;
- L represents a linker of 1, 2, 3 or 4, preferably 1 or 2, linking atom(s) in a linear or in a branched conformation, and being selected from the group consisting of: C, O, N or S, wherein at least one of the linking atoms is oxygen (O);
- R is a saturated or unsaturated C1-6 alkyl, saturated or unsaturated cycloalkyl preferably consisting of 1 or 2 monocyclic rings, saturated or unsaturated heteroalkyl or a saturated or unsaturated heterocyclic ring system consisting of 1 or 2 heterocyclic rings, wherein said alkyl, cycloalkyl, heteroalkyl or ring system may contain at least one substituent, preferably 1-2 or 1-3 substituents, selected from a group consisting of: H, F, Cl, Br, I, C1-3 alkyl, halogen-substituted alkyl, alkoxy, halogen-substituted alkoxy, —CN, —OH, —COOH, —CONH2 and —NO2,
- and wherein L is O, R is not piperidin-4-yl or piperidin-4-yl with a Cl-substituent;
- or a tautomer, stereoisomer or a pharmaceutically acceptable salt thereof;
- for use as a medicine.
- Preferably, said compound has a general formula
- wherein:
- the CLOSURE structure provides part of a 5-7-membered unsaturated or saturated heterocyclic group or alternatively the CLOSURE structure is absent, wherein the CLOSURE structure is replaced by hydrogen atoms H and/or H2;
- L represents a linker of 1, 2, 3 or 4 linking atom(s) in a linear or in a branched conformation, said atom(s) being selected from the group consisting of: C, O, N or S wherein at least one of the linking atoms is oxygen (O);
- R1 is on 2, 3 or 4 position of the phenyl group and is selected from the group consisting of: H, F, Cl, Br, I, C1-3 alkyl, halogen-substituted C1-3 alkyl, C1-3 alkoxy, halogen-substituted C1-3 alkoxy, —CN, —OH, —COOH, —CONH2 and —NO2.
- More preferably, R1 is —CONH2 or a halogen such as F. Linker L is preferably O or C.
- In an embodiment, the CLOSURE structure comprises 1, 2 or 3 carbon atoms, such as structures CH, C2H2 or C3H3. In an embodiment, wherein the CLOSURE structure is absent, the chain of carbon atoms of a heterocyclic group is replaced by hydrogen atoms H and/or H2.
- In the embodiments of the invention, linker L is preferably selected from the group consisting of: O, NH, N(—CH3), C(═O), O—CH2, O—C(═O), C(═O)—O, and O—CH2—CH2—O.
- Accordingly, in linker L the linking atoms can have substituents such as H or H2 or branched structures such as —CH3, or ═O.
- Preferably, said compound is 4,4′-oxydibenzamide having the formula
- wherein L is O; R1 is —CONH2 on 4 position of the phenyl group and the CLOSURE structure is absent.
- In another preferred embodiment, the said compound has a general formula:
- wherein R is as defined above and Li is absent or an extended linker structure selected from a group consisting of: C(═O), CH2, CH(—CH3) and CH2—CH2—O. Preferably, L1 is selected from a group consisting of: C(═O) or CH2.
- In another embodiment, the compound preferably has the formula
- wherein L contains linking atoms A and B. R1 and the CLOSURE structure are as defined above. Linking atoms A and B are selected from the group consisting of: C, O, N or S, wherein at least A or B is oxygen (O). Preferably, the A is oxygen (O) and B is carbon (C), wherein the linker has the structure O—CH2. Other preferred linkers are CH2—O, O—C(═O) or C(═O)—O.
- More preferably, said compound has the formula
- wherein the linker L contains linking atoms oxygen (O) as atom A and carbon (C) as atom B, i.e. the linker is O—CH2, and R1 is fluorine (F) on 2 position of the phenyl group and the CLOSURE structure is not present.
- As used herein, “alkyl” is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms. For example, “C1-3 alkyl” is defined to include groups having 1, 2, or 3 carbons in a linear or branched arrangement. Preferred alkyl groups are methyl (—CH3) and ethyl (—CH2CH3).
- As used herein “halogen-substituted” refers to structures where one or more hydrogen atoms have been replaced by halogen atoms. The term “halogen” refers to fluorine, chlorine, bromine and iodine.
- The term “alkoxy” represents an alkyl group of indicated number of carbon atoms attached through an oxygen bridge. An example of suitable alkoxy groups is C1-3 alkoxy which includes methoxy, ethoxy and propoxy.
- The compounds as defined in Formulas I-V may have asymmetric or chiral structures and thus occur as racemates, racemic mixtures, or as individual diastereomers, or with all possible isomers and mixtures thereof, including optical isomers, all such stereoisomers being in the scope of this description. In addition, the compounds disclosed herein may exist as tautomers and both tautomeric forms are intended to be encompassed by the scope of this description, even though only one tautomeric structure is depicted.
- Preferably, the present compounds are for use in the treatment of cancer. The effect of the present compounds is expected to be larger in cancers where ARTD10 mRNA and subsequently proteins levels are higher than normal cells. Based on this, the preferred applications would be in the treatment of hematopoietic cancers including leukemias and lymphomas, osteosarcoma, breast carcinoma, liver cancer, pancreatic cancer, pancreatic glioma and pancreatic carcinoid.
- Other cancers treatable by the present compounds are carcinomas such as bladder, colon, kidney, lung, including small cell lung cancer, esophagus, gall-bladder, ovary, stomach, cervix, thyroid, prostate, and skin carcinoma, including squamous cell carcinoma; tumors of mesenchymal origin, including fibrosarcoma and rhabdomyosarcoma; tumors of the central and peripheral nervous system, including astrocytoma neuroblastoma, glioma and schwannomas; other tumors, including melanoma, seminoma, teratocarcinoma, xeroderma pigmentosum, keratoxanthoma, thyroid follicular cancer and Kaposi's sarcoma.
- The results also indicate that the present compounds could be used as a general agent to enhance the effect of DNA damaging drugs causing stalling of the replication fork. Therefore, the present compounds are preferably used together with a chemotherapeutic agent such as a DNA damaging compound and/or with radiotherapy. Preferred DNA-damaging anticancer compounds are platinum-based compounds, such as cisplatin, carboplatin, oxaliplatin, and picoplatin, and anthracyclines such as doxorubicin and daunorubicin and also methotrexate. Other preferred DNA-damaging anticancer compounds are topoisomerase I inhibitors such as irinotecan, topotecan, camptothecin and lamellarin D.
- Accordingly, the present compounds are useful in combination with anti-cancer agents or chemotherapeutic agents. The compounds of Formula I may be useful as chemo- and radio-sensitizers for cancer treatment. They are useful for the treatment of patients who have previously undergone or are presently undergoing treatment for cancer. Such previous treatments include prior chemotherapy, radiotherapy, surgery or immunotherapy.
- PARP inhibitors have been demonstrated as being useful for treatment of inflammatory disorders28,29, therefore the present compounds are also for use in the treatment of inflammatory disorders such as acne vulgaris, asthma, autoimmune diseases, autoinflammatory diseases, celiac disease, chronic prostatitis, glomerulonephritis, hypersensitivities, inflammatory bowel diseases, pelvic inflammatory disease, reperfusion injury, rheumatoid arthritis, sarcoidosis, transplant rejection, vasculitis, and interstitial cystitis.
- Treatable patients in this invention include mammalian patients, preferably human patients. This is supported by the fact that the catalytic domain of ARTD10 is conserved in mammals. Catalytic domains of ARTD10 for chimpanzee and human are 99.1% similar. In rhesus macaque (monkey), the similarity is 94.1%. In Guinea pig, the similarity is 75%, but still all the active site residues in the catalytic domain that contribute to the inhibitor binding are conserved. Likewise, the bovine catalytic domain is 74% identical to human and the corresponding homology in sheep is 72.7%.
- In an embodiment, the present invention also relates to pharmaceutical compositions which contain an inhibitor of the Formula I-V or a pharmaceutically acceptable salt thereof as active ingredient. These pharmaceutical compositions are for example those for enteral, such as in particular oral, those for parenteral administration, and those for local administration to a patient.
- The pharmaceutical compositions according to the invention usually contain the pharmacologically active ingredient according to Formula I-V together with known pharmaceutically acceptable carriers, excipients, diluents, adjuvants, fillers, buffers, stabilisers, preservatives or lubricants. The amount of the active ingredient in the pharmaceutical compositions according to the invention is, for example, from about 0.001% to 100% by weight, preferably from about 0.1% to about 50% by weight. The dose of the active ingredient can depend on various factors, such as the efficacy of the active ingredient, severity of the disease to be treated or its symptoms, administration procedure, sex, age, weight and/or individual condition of the subject in need of the treatment. In a normal case, for a human adult of about 75 kg in weight, one daily dose of about 1 mg to about 1000 mg, in particular from about 10 mg to about 500 mg, is to be estimated. This can be administered as a single dose or in several sub-doses.
- In an embodiment, the pharmaceutical compositions may be in the form of an injectable aqueous solution. The injectable preparation may also be an injectable oil-in-water microemulsion where the active ingredient is dissolved in the oily phase. The injectable solutions or microemulsions may be introduced into a patient's blood stream by local bolus injection. The pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension for intramuscular and subcutaneous administration. This suspension may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents.
- The preparation of typical pharmaceutically acceptable salts is described by Berge et al. (1977) J. Pharm. Sci. “Pharmaceutical Salts”, 66: 1-19.
- In an embodiment, the present invention is also directed to the use of the compound as defined by Formula I, Ib, II, III, IV or V for the manufacture of a medicament, preferably for the treatment of cancer or inflammatory disorders. Advantageously, said compound is used together with a chemotherapeutic agent and/or with radiotherapy as described above.
- In an embodiment, the present invention is directed to a method of treating cancer or inflammatory disorder comprising a step of administering the compound as defined by Formula I, Ib, II, III, IV or V to a patient suffering from a cancer or inflammatory disorder.
- The present invention also provides a use of the compound as defined by Formula I, Ib, II, III, IV or V as a mono ADP-ribosyltransferase (mARTD) inhibitor in vitro, preferably as an ARTD10 inhibitor in vitro. The present invention is thus directed to an in vitro method comprising a step contacting the compound as defined by Formula I, Ib, II, III, IV or V with a sample suspected or known to comprise mARTDs, preferably ARTD10, in order to inhibit activity of the mARTDs in the sample. Preferably, said method comprises a further step of contacting said compound with a control sample comprising a mono ADP-ribosyltransferase (mARTD) such as ARTD10.
- In an further embodiment, the present invention is also directed to an in vitro screening method for identifying inhibitors of a mono ADP-ribosyltransferase (mARTD), preferably
ARTD 10, comprising: - a) contacting a candidate compound having a general formula
- wherein:
- the CLOSURE structure provides part of a 5-7-membered unsaturated or saturated heterocyclic group or alternatively the CLOSURE structure is absent, wherein the CLOSURE structure is replaced by hydrogen atoms H and/or H2;
- L represents a linker of 1, 2, 3, or 4, preferably 1 or 2, linking atom(s) in a linear or in a branched conformation, said atom(s) being selected from the group consisting of: C, O, N or S;
- R is a saturated or unsaturated C1-6 alkyl, saturated or unsaturated cycloalkyl preferably consisting of 1 or 2 monocyclic rings, saturated or unsaturated heteroalkyl or a saturated or unsaturated heterocyclic ring system consisting of 1 or 2 heterocyclic rings, wherein said alkyl, cycloalkyl, heteroalkyl or ring system may contain at least one substituent selected from a group consisting of: H, F, Cl, Br, I, C1-3 alkyl, halogen-substituted C1-3 alkyl, C1-3 alkoxy, halogen-substituted C1-3 alkoxy, —CN, —OH, —COOH, —CONH2 and —NO2;
- or a tautomer, stereoisomer or a pharmaceutically acceptable salt thereof;
- with a mono ADP-ribosyltransferase;
- b) measuring the level of enzymatic activity of the mono ADP-ribosyltransferase in the presence of said candidate compound;
- c) selecting those candidate compounds which inhibit the mono ADP-ribosyltransferase.
- Preferably, the candidate compound selected in step c) can rescue cells overexpressing said mono ADP-ribosyltransferase. the candidate compound selected in step c) is tested to be a selective inhibitor of said mono ADP-ribosyltransferase.
- Having now generally described the invention, the same will be more readily understood by reference to the following Experimental Section, which is provided by way of illustration and is not intended as limiting.
- Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below.
- Used Proteins
- All the proteins used in the study were produced recombinantly in E. coli host. Details for the amino acid composition of each construct are described in Tables 1 and 2. Proteins were purified using affinity chromatography (Ni-NTA) and size-exclusion chromatography. DNA binding ARTDs were further purified on a heparin column before performing the size-exclusion chromatography. In some cases the 6x his-tag was cleaved from the fusion proteins (ARTD12, ARTD15). The protocol described above summarizes the general purification method followed for all the proteins used in this study. More details about constructs used in different assays are given in Tables 1 and 2.
- Differential Scanning Fluorimetry
- Differential scanning fluorimetry was performed with protein concentrations of 0.25 mg/ml. Details of the expression constructs used for each ARTD are provided in Table 1. The concentration of OUL35 was 100 μM. Control wells without the compound contained an equal amount of the DMSO vehicle as the melting curves in the presence of OUL35. Sypro Orange (Life Technologies) was used as the reporter dye with a final concentration of 20×. The experiment was performed on a real time PCR machine (Applied Biosystems) with the temperature increasing from 21° C. up to 90° C. (70 cycles) with 1 degree increment per minute.
-
TABLE 1 Details of the constructs used for performing thermal stability assay. ARTD Amino Acid composition ARTD1 654-1013 ARTD2 234-579 ARTD3 176-532 ARTD4 250-565 ARTD5 1091-1325 ARTD6 952-1161 ARTD7 460-656 ARTD8 1611-1801 ARTD10 809-1017 ARTD10 (G888W) 809-1017 ARTD10 (L926Y) 809-1017 ARTD10 (R931A) 809-1017 ARTD12 489-684 ARTD13 726-896 ARTD15 1-280 - Activity Assays
- Screening of the compound libraries against ARTD10 was performed based on our previously validated activity-based fluorescent assay16. Profiling and dose response experiments were conducted as described previously16,18. As detailed in our earlier publication16 some of the mARTDs are very sensitive to increasing concentrations of DMSO. In these cases we tested a maximum concentration of 10 μM for compound OUL35. Details of the assay conditions and expression constructs used for each ARTD are provided in Table 2.
-
TABLE 2 Constructs and conditions used in the activity assays. Amino ARTD Acids Assay Conditions ARTD1 1-1014 5 nM ARTD1 and NAD+ 500 nM 50 mM Tris pH 8, 2 mM Mg2+, 10 μg/mL activated DNA 1.5 h shaking at RT ARTD2 1-583 5 nM ARTD2 and NAD+ 500 nM 50 mM Tris pH 8, 5 mM Mg2+, 10 μg/mL activated DNA 1.5 h shaking at RT ARTD3 1-533 200 nM ARTD3 and 500 nM NAD+ 50 mM HEPES pH 7, 10 μg/mL DNA, 8 mM MgC12 3 h shaking at RT ARTD4 250-565 200 nM ARTD4 and 500 nM NAD+ 50 mM Na-P buffer pH 7.5, 0.5 mM TCEP, 1 mg/mL BSA 2.5 h shaking at RT ARTD5 1030-1317 20 nM ARTD5 and 500 nM NAD+ 50 mM BisTris propane pH 7, 0.5 mM TCEP, 0.01% Triton X-100 18 h shaking at RT 20 nM ARTD6 and 500 nM NAD+ ARTD6 873-1161 50 mM BisTris propane pH 7, 0.5 mM TCEP, 18 h shaking at RT /300 rpm ARTD7 460-656 200 nM ARTD7, 500 nM SRPK2 and 250 nM NAD+ 50 mM Na-P pH 7 8 h shaking at RT ARTD8 1535-1801 500 nM ARTD8 and 250 nM NAD+ 50 mM Na-P pH 7.0 21 h shaking at RT ARTD10 809-1017 100 nM ARTD10, 2 μM SRPK2 and 500 nM NAD+ 50 mM Tris pH 7.0 13 h shaking at RT ARTD12 489-701 500 nM ARTD12 and 500 nM NAD+ 50 mM Na-P pH 7 20 h shaking at RT ARTD15 1-280 2 μM ARTD15 and 500 nM NAD+ 50 mM HEPES ph 7, 2 mM NiCl2 24 h shaking at RT - Docking of OUL35
- GOLD27 was used to analyze the binding mode of OUL35 to the catalytic domain of ARTD10. The available ARTD10 crystal structure (3HKV) contains mutations, but they are located outside the expected binding pocket and do not contribute to the binding of OUL35. The binding pocket was defined with an 8 A radius based on the nicotinamide mimicking 3AB present in the crystal structure. Hydrogen atoms were added, ligands and water molecules removed, and the program defaults were used with the ChemPLP scoring function. The top three binding poses produced by the genetic algorithm were essentially the same indicating a likely solution in the docking experiment.
- Colony Formation Assay
- Three hundred HeLa cells designed to express the wild-type ARTD10 and catalytically inactive ARTD10 (G888W) in response to doxycycline were seeded in 6 cm well culture plates. The cells were grown in DMEM culture media with 10% FCS, and the plates were incubated at 37° C. with 5% CO2. After 24 h of seeding, over expression of ARTD10 was induced by adding 500 ng/ml doxycycline and the media were also supplemented with the tested compounds at 10 μM concentrations. The cells were allowed to proliferate for the next 10 days, after which they were stained with methylene blue to count the number of surviving colonies. The compounds and doxycycline were replenished every 48 h while fresh media (DMEM supplemented with 10% FCS) was added every four days.
- DNA Damage Experiments
- HeLa cells (ATCC) were grown in Dulbecco's modified Eagle's medium (DMEM, Sigma) supplemented with 10% fetal bovine serum (Lonza), 1× penicillin and streptomycin (Sigma) at 37° C. in a 5% CO2 atmosphere. 4000 cells/well were plated on 96-well plates. The cells were allowed to attach for 6 hours before treatment with hydroxyurea combined with 5 μM OUL35 or DMSO vehicle in serum free medium. The DMSO content was kept below 0.05% in all experiments. The 96-well plates were placed in an IncuCyte ZOOM live cell imaging system (Essen BioScience) to follow the cell growth. The plates were scanned in the IncuCyte at 2 hour intervals for 72 hours. Data were analyzed by the IncuCyte Zoom software (Essen BioScience). The results are representative of three (cell growth curves) or five independent experiments (72 h end points) each done in six replicates. P values less than 0.05 were considered as significant (n.s=not statistically significant, *P<0.05, **P<0.01).
- Results
- Discovery of a Potent and Selective ARTD10 Inhibitor
- Earlier we described a robust activity-based assay for ARTD10, which was validated for screening of compound libraries16. Here we applied this assay for the screening of compound libraries from the open chemical repository of the National Cancer Institute (NCI). Dose response measurements of the hit compound revealed OUL35 (4,4′-oxydibenzamide), which had an IC50 value of 329 nM (
FIG. 1 ). Treatment of HeLa cells with 10 μM of OUL3 5 showed that OUL35 has no cytotoxic effect. - Profiling and Selectivity
- There are 17 ARTD enzymes in the human ARTD superfamily, which all contain a homologous catalytic domain. Therefore it was essential to verify the selectivity of OUL35 for ARTD10. The non-selectivity of the “PARP inhibitors” is a known issue and some efforts have recently been devoted to understanding the inhibitor profile11,17. We used our established assay method16,18 to profile the selectivity of OUL35 against the ARTDs available in our laboratory (Table 3). Profiling experiments revealed that OUL35, despite its small molecular weight and simple structure, was highly selective towards ARTD10 over the other enzymes of the family (Table 3). OUL35 also inhibited ARTD8 (23.4 μM), ARTD4 (22.6 μM), and ARTD15 (4.17 μM) but with modest potency (Table 3). Selectivity was further validated by differential scanning fluorimetry (DSF) to test for binding of the compound. This activity independent method also allowed us to include inactive ARTD13 in the profiling. DSF verified binding of OUL35 to the ARTD10 catalytic domain and its selectivity over other ARTDs. OUL35 stabilized the catalytic domains of ARTD10, ARTD8 & ARTD15 as expected based on the enzymatic assays (Table 3).
-
TABLE 3 IC50 and thermal stabilization of oUL35 against a panel of human ARTD enzymes. ARTD/PARP IC50 (pIC50 ± SEM) ΔTm (DSF), ° C. ± STDEV ARTD1/PARP1 >100 μM 0.42 ± 0.09 ARTD2/PARP2 >100 μM 0.15 ± 0.12 ARTD3/PARP3 >100 μtM 0.09 ± 0.32 ARTD4/PARP4 22.6 μM (4.65 ± 0.17) 0.84 ± 0.14 ARTD5/PARP5a >100 μM 0.45 ± 0.01 ARTD6/PARP5b >100 μM 0.15 ± 0.12 ARTD7/PARP15 >20 μMa 1.19 ± 0.10 ARTD8/PARP14 23.4 μM (4.63 ± 0.09) 3.00 ± 0.21 ARTD10/PARP10 329 nM (6.48 ± 0.04) 3.76 ± 0.10 ARTD12/PARP12 >100 μM 0.87 ± 0.42 ARTD13/PARP13 ND −0.21 ± 0.04 ARTD15/PARP16 4.17 μM (5.38 ± 0.06) 2.45 ± 0.11 aCompound concentration limited by ARTD DMSO sensitivity. Less than 50% inhibition was observed when tested at 20 concentration. - OUL35 contains a nicotinamide mimicking motif like most of the ARTD inhibitors reported to date11 (
FIG. 1 ). It consists of two symmetrical benzamide motifs that could compete with the binding of NAD+ in the nicotinamide binding site. Based on this hypothesis we designed two small modifications to the compound yielding OUL77 and OUL78, which we expected to be inactive and useful as control compounds when evaluating OUL35 in biological systems (FIG. 1 ). Neither of the methylated analogs at concentrations of 1 μM or 10 μM inhibited ARTD10 supporting our results. Based on the biochemical and biophysical analysis OUL35 is a potentially useful tool to study ARTD10 functions in cells. - Modelling
- To understand the structural basis for inhibition and selectivity of OUL35 against ARTD10 we performed docking studies using the available crystal structure of an ARTD10 mutant (PDB id. 3HKV). There are no NAD+ complex structures with ARTDs available and our understanding of the substrate binding is based on the NAD+ binding mode in the diphtheria toxin19 (PDB id. 1TOX) and on NAD+ mimicking inhibitors17. The crystal structure of ARTD10 contains a small general ARTD inhibitor 3-aminobenzamide (3AB), which binds to the nicotinamide binding site of ARTDs (
FIG. 1 ). The chemical structure of OUL35 suggests that the benzamide moiety would bind to the nicotinamide pocket in a manner similar to the nicotinamide of the substrate NAD+ and the small general ARTD inhibitor 3AB (FIG. 1 ). Based on this assumption, we expect that OUL35 extends from the pocket towards the acceptor site where the ADP-ribosylation target protein binds. The acceptor site is deduced from the NAD+ analog found partially visible in the chicken ARTD1 structure20. Docking studies revealed that the best binding pose indeed overlaps with 3AB found in the co-crystal structure and that OUL35 extends towards the acceptor site (FIG. 2 ). - OUL35 Rescues HeLa Cells from ARTD10-Induced Cell Death
- Over-expression of wild-type ARTD10 but not the catalytically inactive mutant ARTD10-G888W leads to cell death8. Colony formation assays were performed to assess whether OUL35 can enter cells and inhibit endogenous ARTD10 and whether the toxic effect of ARTD10 could be rescued by inhibiting its ADP-ribosylation activity. As expected, overexpression of wild-type ARTD10 but not ARTD10-G888W strongly inhibited cell proliferation (
FIG. 3a, b ). The treatment of HeLa cells overexpressing ARTD10 with OUL35 resulted in a complete rescue of cell proliferation. Notably the inactive analogs OUL77 and OUL78 were ineffective and did not facilitate colony formation (FIG. 3 ). Moreover none of the compounds showed any toxicity in the control cells. Together these findings provide evidence that OUL35 is taken up by cells and inhibits the catalytic activity of ARTD10. - Hydroxyurea Sensitivity Confirms the Role of ARTD10 in Genotoxic Stress Response
- Hydroxyurea (HU) inhibits ribonucleotide reductase and thus interferes with deoxyribonucleotide synthesis. This results in inhibition of S phase and causes stalled replication forks21. ARTD10 knockdown cells are more sensitive to HU-induced DNA damage as the catalytic activity is necessary for its DNA repair functions5. We investigated whether we could reproduce this effect by inhibiting the enzymatic activity of ARTD10 in HeLa cells. HeLa cells treated with HU were more sensitive to DNA damage in the presence of OUL35 (
FIG. 4 ). Thus using a specific chemical probe we confirmed that the enzymatic activity of ARTD10 is indeed required for the recovery of the cells from the hydroxyurea induced genotoxic stress. - Discussion
- Here, the small molecule OUL35 was identified as a selective inhibitor of one of the mARTDs-ARTD10. The compound is able to enter cultured cells and inhibit ARTD10-dependent cellular processes. Structural analysis suggested the basis of the selectivity over the other ARTD enzymes and the docking model indicated that OUL35 would be the first ARTD/PARP inhibitor extending towards the acceptor site. While OUL35 is selective towards ARTD10 it can also be used in the design of other mARTD inhibitors due to the structural similarities of the binding sites. Notably, the identified mARTDs that show weak affinity to OUL35 are also suggested to be involved in cancer linked processes. ARTD8 plays a role in the survival of cancerous multiple myeloma cells26 and promotes DNA damage repair6, while ARTD15 is a regulator of the unfolded protein response7.
- OUL35 was not toxic to control cells in our experiments, but it efficiently rescued cells overexpressing ARTD10 and reproduced the effects seen by ARTD10 knockdown using RNAi5,8. The results provide additional evidence for the role of ARTD10 in S phase DNA damage repair. OUL35 will aid further studies to assess the roles of ARTD10 in different processes.
- Various R substituents are effective in the scaffold as described in Formula (I). The compounds were assayed for the inhibition of ARTD10 activity as described above and examples of the effective groups in the contexts of the variable linkers are shown in
FIGS. 5-7 . These results show that the minimum R group in the context of a one atom linker (L) is a methyl group, although the increase of the size improves the potency like in the case of a cyclobutyl. Also a large bulky naphtalenyl group is tolerated as an R group. -
-
- 1. Amé, J.-C., Spenlehauer, C. & de Murcia, G. The PARP superfamily. BioEssays 26, 882-893 (2004).
- 2. Otto, H. et al. In silico characterization of the family of PARP-like poly(ADP-ribosyl)transferases (pARTs).
BMC Genomics 6, 139 (2005). - 3. Hottiger, M. O., Hassa, P. O., Lüscher, B., Schiller, H. & Koch-Nolte, F. Toward a unified nomenclature for mammalian ADP-ribosyltransferases. Trends Biochem. Sci. 35, 208-219 (2010).
- 4. Kleine, H. et al. Substrate-Assisted Catalysis by PARP10 Limits Its Activity to Mono-ADP-Ribosylation. Mol. Cell 32, 57-69 (2008).
- 5. Nicolae, C. M. et al. The ADP-ribosyltransferase PARP10/ARTD10 Interacts with Proliferating Cell Nuclear Antigen (PCNA) and Is Required for DNA Damage Tolerance. J. Biol. Chem. 289, 13627-13637 (2014).
- 6. Nicolae, C. M. et al. A novel role for the mono-ADP-ribosyltransferase PARP14/ARTD8 in promoting homologous recombination and protecting against replication stress. Nucleic Acids Res. 43, 3143-3153 (2015).
- 7. Jwa, M. & Chang, P. PARP16 is a tail-anchored endoplasmic reticulum protein required for the PERK- and IRE1a-mediated unfolded protein response. Nat. Cell Biol. 14, 1223-1230 (2012).
- 8. Herzog, N. et al. Caspase-dependent cleavage of the mono-ADP-ribosyltransferase ARTD10 interferes with its pro-apoptotic function. FEBS J. 280, 1330-1343 (2013).
- 9. Verheugd, P. et al. Regulation of NF-idB signalling by the mono-ADP-ribosyltransferase ARTD10. Nat. Commun. 4, 1683 (2013).
- 10. Feijs, K. L. et al. ARTD10 substrate identification on protein microarrays: regulation of GSK3f3 by mono-ADP-ribosylation. Cell Commun. Signal. 11, 5 (2013).
- 11. Wahlberg, E. et al. Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors. Nat. Biotechnol. 30, 283-288 (2012).
- 12. Vyas, S. & Chang, P. New PARP targets for cancer therapy. Nat. Rev. Cancer 14, 502-509 (2014).
- 13. Feijs, K. L. H., Verheugd, P. & Liischer, B. Expanding functions of intracellular resident mono-ADP-ribosylation in cell physiology. FEBS J. 280, 3519-3529 (2013).
- 14. Bütepage, M., Eckei, L., Verheugd, P. & Lüscher, B. Intracellular Mono-ADP-Ribosylation in Signaling and Disease. Cells 4, 569-595 (2015).
- 15. Yu, M. et al. PARP-10, a novel Myc-interacting protein with poly(ADP-ribose) polymerase activity, inhibits transformation. Oncogene 24, 1982-1993 (2005).
- 16. Venkannagari, H., Fallarero, A., Feijs, K. L. H., Liischer, B. & Lehtiö, L. Activity-based assay for human mono-ADP-ribosyltransferases ARTD7/PARP15 and ARTD10/PARP10 aimed at screening and profiling inhibitors. Eur. J. Pharm. Sci. 49, 148-156 (2013).
- 17. Haikarainen, T., Narwal, M., Joensuu, P. & Lehtiö, L. Evaluation and Structural Basis for the Inhibition of Tankyrases by PARP Inhibitors. ACS Med. Chem. Lett. 5, 18-22 (2014).
- 18. Narwal, M., Fallarero, A., Vuorela, P. & Lehtiö, L. Homogeneous screening assay for human tankyrase. J. Biomol. Screen. 17, 593-604 (2012).
- 19. Bell, C. E. & Eisenberg, D. Crystal structure of diphtheria toxin bound to nicotinamide adenine dinucleotide. Biochemistry (Mosc.) 35, 1137-1149 (1996).
- 20. Ruf, A., Rolli, V., de Murcia, G. & Schulz, G. E. The mechanism of the elongation and branching reaction of poly(ADP-ribose) polymerase as derived from crystal structures and mutagenesis. J. Mol. Biol. 278, 57-65 (1998).
- 21. Koc, A., Wheeler, L. J., Mathews, C. K. & Merrill, G. F. Hydroxyurea Arrests DNA Replication by a Mechanism That Preserves Basal dNTP Pools. J. Biol. Chem. 279, 223-230 (2004).
- 22. Ekblad, T. et al. Towards small molecule inhibitors of mono-ADP-ribosyltransferases. Eur. J. Med. Chem. 95, 546-551 (2015).
- 23. Morgan, R. K., Carter-O'Connell, I. & Cohen, M. S. Selective inhibition of PARP10 using a chemical genetics strategy. Bioorg. Med. Chem. Lett. (2015). doi:10.1016/j .bmc1.2015.07.033
- 24. Andersson, C. D. et al. Discovery of ligands for ADP-ribosyltransferases via docking-based virtual screening. J. Med. Chem. 55, 7706-7718 (2012).
- 25. Scarpa, E. S., Fabrizio, G. & Di Girolamo, M. A role of intracellular mono-ADP-ribosylation in cancer biology. FEBS J. 280, 3551-3562 (2013).
- 26. Barbarulo, A. et al. Poly(ADP-ribose) polymerase family member 14 (PARP14) is a novel effector of the JNK2-dependent pro-survival signal in multiple myeloma. Oncogene 32,4231-4242 (2013).
- 27. Jones, G., Willett, P., Glen, R. C., Leach, A. R. & Taylor, R. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 267,727-748 (1997).
- 28. Cuzzocrea, S. Shock, inflammation and PARP. Pharmacological Research Volume 52,
Issue 1, July 2005, Pages 72-82. - 29. Virág, L. Poly(ADP-ribosyl)ation in asthma and other lung diseases. Pharmacological Research Volume 52,
Issue 1, July 2005, Pages 83-92. - 30. Lord C J, Tutt A N, and Ashworth A. Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors. Annu Rev Med. 2015;66:455-70.
- Cited Patent Documents:
- EP1500643
- U.S. Pat. No. 8,993,594
- U.S. Pat. No. 8,980,902
- US2015031652
- WO2015051766
- WO2014201972
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/380,195 US20210346322A1 (en) | 2016-04-06 | 2021-07-20 | Compounds for use in the treatment of cancer |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FI20165300 | 2016-04-06 | ||
FI20165300 | 2016-04-06 | ||
PCT/FI2017/050247 WO2017174879A1 (en) | 2016-04-06 | 2017-04-06 | Compounds for use in the treatment of cancer |
US201816091551A | 2018-10-05 | 2018-10-05 | |
US17/380,195 US20210346322A1 (en) | 2016-04-06 | 2021-07-20 | Compounds for use in the treatment of cancer |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FI2017/050247 Division WO2017174879A1 (en) | 2016-04-06 | 2017-04-06 | Compounds for use in the treatment of cancer |
US16/091,551 Division US11096909B2 (en) | 2016-04-06 | 2017-04-06 | Compounds for use in the treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
US20210346322A1 true US20210346322A1 (en) | 2021-11-11 |
Family
ID=58638869
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/091,551 Active US11096909B2 (en) | 2016-04-06 | 2017-04-06 | Compounds for use in the treatment of cancer |
US17/380,195 Pending US20210346322A1 (en) | 2016-04-06 | 2021-07-20 | Compounds for use in the treatment of cancer |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/091,551 Active US11096909B2 (en) | 2016-04-06 | 2017-04-06 | Compounds for use in the treatment of cancer |
Country Status (3)
Country | Link |
---|---|
US (2) | US11096909B2 (en) |
EP (1) | EP3440052B1 (en) |
WO (1) | WO2017174879A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017174879A1 (en) * | 2016-04-06 | 2017-10-12 | University Of Oulu | Compounds for use in the treatment of cancer |
CN111607577A (en) * | 2020-05-09 | 2020-09-01 | 李健 | PARP15 protein and 3-aminobenzamide compound crystal serving as inhibitor thereof and preparation method of compound crystal |
WO2023144450A1 (en) | 2022-01-28 | 2023-08-03 | Oulun Yliopisto | Compounds for use in the treatment of cancer and inflammatory conditions |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3983164A (en) * | 1973-08-23 | 1976-09-28 | Beecham Group Limited | Phenyl alkyleneoxy phenyl alkanoic acid esters |
US11096909B2 (en) * | 2016-04-06 | 2021-08-24 | University Of Oulu | Compounds for use in the treatment of cancer |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1437781A (en) * | 1972-04-04 | 1976-06-03 | Beecham Group Ltd | Pyridine derivatives having hypoglycaemic activity |
AU2003220935A1 (en) | 2002-04-03 | 2003-10-13 | Sumitomo Pharmaceuticals Company, Limited. | Benzamide derivatives |
PT1910333E (en) * | 2005-07-26 | 2013-08-01 | Sanofi Sa | Piperidinyl-substituted isoquinolone derivatives as rho-kinase inhibitors |
WO2008024139A2 (en) * | 2006-08-18 | 2008-02-28 | N.V. Organon | Inhibitors of fatty acid amide hydrolase |
CN101522609A (en) | 2006-09-05 | 2009-09-02 | 彼帕科学公司 | Treatment of cancer |
US7732491B2 (en) * | 2007-11-12 | 2010-06-08 | Bipar Sciences, Inc. | Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents |
KR101779137B1 (en) | 2009-01-23 | 2017-09-18 | 다케다 야쿠힌 고교 가부시키가이샤 | Poly(adp-ribose)polymerase(parp) inhibitors |
WO2010100475A1 (en) | 2009-03-02 | 2010-09-10 | Astrazeneca Ab | Hydroxamic acid derivatives as gram-negative antibacterial agents |
AT508094B1 (en) | 2009-03-31 | 2015-05-15 | Fronius Int Gmbh | METHOD AND DEVICE FOR OPERATING A POWER SOURCE ASSOCIATED WITH A HAND-HELD WORK EQUIPMENT |
TWI499418B (en) | 2009-05-21 | 2015-09-11 | Nerviano Medical Sciences Srl | Isoquinolin-1(2h)-one derivatives |
US8541417B2 (en) | 2009-07-30 | 2013-09-24 | Takeda Pharmaceutical Company Limited | Poly (ADP-ribose) polymerase (PARP) inhibitors |
WO2011017142A1 (en) * | 2009-08-06 | 2011-02-10 | Merck Patent Gmbh | Novel bicyclic urea compounds |
CN104230896A (en) | 2013-06-17 | 2014-12-24 | 上海汇伦生命科技有限公司 | Benzimidazole-2-piperazine heterocycle ramification and medicine composition as well as preparation method and application thereof |
TWI522352B (en) | 2013-10-12 | 2016-02-21 | 貝達藥業股份有限公司 | Amids substituted indazole derivatives as poly (adp-ribose) polymerase inhibitors |
CN104163772A (en) | 2014-05-28 | 2014-11-26 | 厦门大学 | Substituted diaryl ester compound, and preparation method and application thereof |
KR20180070695A (en) * | 2015-10-29 | 2018-06-26 | 이펙터 테라퓨틱스, 인크. | The isoindoline, azoisopyrindine, dihydroindene and dihydroazaindene inhibitors of MNK1 and MNK2 |
-
2017
- 2017-04-06 WO PCT/FI2017/050247 patent/WO2017174879A1/en active Application Filing
- 2017-04-06 US US16/091,551 patent/US11096909B2/en active Active
- 2017-04-06 EP EP17719861.1A patent/EP3440052B1/en active Active
-
2021
- 2021-07-20 US US17/380,195 patent/US20210346322A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3983164A (en) * | 1973-08-23 | 1976-09-28 | Beecham Group Limited | Phenyl alkyleneoxy phenyl alkanoic acid esters |
US11096909B2 (en) * | 2016-04-06 | 2021-08-24 | University Of Oulu | Compounds for use in the treatment of cancer |
Non-Patent Citations (2)
Title |
---|
"Overview of pharmaceutical excipients used in tablets and capsules." Drug Topics. (October 24, 2008). Accessed 30 June 2023. Available from: < https://www.drugtopics.com/view/overview-pharmaceutical-excipients-used-tablets-and-capsules >). (Year: 2008) * |
Venkannagari, H., et al. "Small-Molecule Chemical Probe Rescues Cells from Mono-ADP-Ribosyltransferase ARTD10/PARP10-Induced Apoptosis and Sensitizes Cancer Cells to DNA Damage." Cell Chemical Biology. (2016), Vol. 23, pp. 1251-1260. (Year: 2016) * |
Also Published As
Publication number | Publication date |
---|---|
US20190105289A1 (en) | 2019-04-11 |
EP3440052A1 (en) | 2019-02-13 |
WO2017174879A1 (en) | 2017-10-12 |
US11096909B2 (en) | 2021-08-24 |
EP3440052B1 (en) | 2023-10-25 |
EP3440052C0 (en) | 2023-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210346322A1 (en) | Compounds for use in the treatment of cancer | |
Lang et al. | Nitrogen-containing heterocycles as anticancer agents: An overview | |
Roberts et al. | Molecular insights into microbial β-glucuronidase inhibition to abrogate CPT-11 toxicity | |
Jagtap et al. | Poly (ADP-ribose) polymerase and the therapeutic effects of its inhibitors | |
KR20150093695A (en) | Small molecule inhibitors of malt1 | |
ES2672468T3 (en) | Deuterated Momelotinib | |
ES2958528T3 (en) | Substituted macrocycles useful as kinase inhibitors | |
Govender et al. | Spiropyrimidinetrione DNA gyrase inhibitors with potent and selective antituberculosis activity | |
Kim et al. | Synthesis and SAR of pyrrolotriazine-4-one based Eg5 inhibitors | |
KR102374033B1 (en) | specific protein kinase inhibitors | |
US10633367B2 (en) | Fluorine- and/or deuterium-containing compounds for treating non-small cell lung cancer and related diseases | |
Lei et al. | Discovery of novel mutant-combating ALK and ROS1 dual inhibitors bearing imidazolidin-2-one moiety with reasonable PK properties | |
Papeo et al. | Poly (ADP-ribose) polymerase inhibition in cancer therapy: are we close to maturity? | |
US20230159498A1 (en) | Small molecules for the treatment of autoimmune diseases and cancer | |
KR20150041786A (en) | Combination therapy for the treatment of cancer and immunosuppression | |
Wang et al. | Discovery of 2-(aminopyrimidin-5-yl)-4-(morpholin-4-yl)-6-substituted triazine as PI3K and BRAF dual inhibitor | |
Chamariya et al. | Role of KSP inhibitors as anti-cancer therapeutics: an update | |
Dou et al. | Discovery of novel ataxia telangiectasia mutated (ATM) kinase modulators: computational simulation, biological evaluation and cancer combinational chemotherapy study | |
Wei et al. | Recent development of cyclic amide (pyridone/lactam) moiety containing heterocycles as protein kinase inhibitors | |
CN105793421A (en) | Resistant mutant 90 kDa heat shock protein | |
JP2021088508A (en) | Sarcoma treating agent | |
AU2020374269A1 (en) | Novel heterocyclic-substituted pyrimidine derivative exhibiting cancer cell growth inhibitory effect, and pharmaceutical composition containing same | |
Lin et al. | Design, synthesis, and characterization of novel CXCR4 antagonists featuring cyclic amines | |
WO2020210662A1 (en) | Small molecules for cancer therapy that reduce the expression of transcription factors klf5 and egr-1 | |
Li et al. | Structure-Guided Design and Synthesis of Pyridinone-Based Selective Bromodomain and Extra-Terminal Domain (BET)-First Bromodomain (BD1) Inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: UNIVERSITY OF OULU, FINLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LEHTIOE, LARI;VENKANNAGARI, HARIKANTH;LUESCHER, BERNHARD;AND OTHERS;SIGNING DATES FROM 20181029 TO 20181031;REEL/FRAME:057804/0619 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |